Patents by Inventor Mohamed Albed Alhnan
Mohamed Albed Alhnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165040Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.Type: ApplicationFiled: June 16, 2023Publication date: May 23, 2024Inventors: Mohamed ALBED ALHNAN, Tochukwu Chijioke OKWUOSA
-
Publication number: 20240156739Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.Type: ApplicationFiled: August 7, 2023Publication date: May 16, 2024Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20240148657Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.Type: ApplicationFiled: August 7, 2023Publication date: May 9, 2024Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20240041776Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.Type: ApplicationFiled: March 10, 2023Publication date: February 8, 2024Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Patent number: 11771655Abstract: The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.Type: GrantFiled: September 8, 2015Date of Patent: October 3, 2023Assignee: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Patent number: 11717485Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.Type: GrantFiled: June 4, 2021Date of Patent: August 8, 2023Assignee: University of Central LancashireInventors: Mohamed Albed Alhnan, Tochukwu Chijoke Okwuosa
-
Patent number: 11622940Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.Type: GrantFiled: February 18, 2021Date of Patent: April 11, 2023Assignee: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20220331255Abstract: The present invention relates to solid dosage forms comprising coatings based on natural ingredients, such as naturally-occuring esterified and non-esterified polyuronic acids, optionally in combination with stabilising lipophilic component(s) (e.g. surfactant(s)) and/or other stabilising components. The inventors have made the surprising discovery that polysaccharide-based coatings can be stabilised, and often imparted with gastric resistant properties, through the inclusion of particular additives and/or additional layers. In particular, polyuronic acid-containing coatings may be stabilised and rendered more robust through the inclusion of a lipophilic component (e.g. surfactant), an esterified polyuronic acid, and/or the deployment of an additional coating layer containing stabilising agents that affect the disintegration and/or dissolution of the polyuronic acid.Type: ApplicationFiled: April 28, 2017Publication date: October 20, 2022Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20210369622Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.Type: ApplicationFiled: February 18, 2021Publication date: December 2, 2021Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20210353547Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.Type: ApplicationFiled: June 4, 2021Publication date: November 18, 2021Inventors: Mohamed ALBED ALHNAN, Tochukwu Chijoke OKWUOSA
-
Patent number: 11045426Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.Type: GrantFiled: July 25, 2017Date of Patent: June 29, 2021Assignee: UNIVERSITY OF CENTRAL LANCASHIREInventors: Mohamed Albed Alhnan, Tochukwu Chijioke Okwuosa
-
Publication number: 20210169809Abstract: The present invention provides methods of preparing solid dosage form, particularly pharmaceutical dosage forms, using extrusion and 3D-printing, as well as the solid dosage form itself, the compositions used to make said items, uses of the solid dosage forms, and containers used in their preparation.Type: ApplicationFiled: August 13, 2019Publication date: June 10, 2021Inventor: Mohamed Albed Alhnan
-
Patent number: 10952969Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.Type: GrantFiled: October 31, 2016Date of Patent: March 23, 2021Assignee: University of Central LancashireInventor: Mohamed Albed Alhnan
-
Publication number: 20200146994Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.Type: ApplicationFiled: July 25, 2017Publication date: May 14, 2020Inventors: Mohamed ALBED ALHNAN, Tochukwu Chijioke OKWUOSA
-
Publication number: 20190125681Abstract: The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.Type: ApplicationFiled: September 8, 2015Publication date: May 2, 2019Applicant: University of Central LancashireInventor: Mohamed ALBED ALHNAN
-
Publication number: 20180311169Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.Type: ApplicationFiled: October 31, 2016Publication date: November 1, 2018Applicant: University of Central LancashireInventor: Mohamed Albed Alhnan